Eliminating Barriers
to Global Vaccination
Approach
Approach



Technology
1. Maintaining thermostability during transport and storage
2. The need to administer multiple doses to provide a robust immune response against infection or disease
VitriVax has engineered its proprietary Atomic Layering Thermostable Antigen and Adjuvant (ALTA) technology platform to enable thermostable, single-shot vaccines across a broad range of indications, while maintaining or potentially even enhancing the immune response of vaccines. ALTA can be applied to a wide variety of vaccine antigens and adjuvants to protect against thermal and chemical degradation and enable controlled release, incorporating prime doses + additional booster doses in a single-shot administration. These technologies may also facilitate co-formulation of multiple otherwise incompatible antigens in a single injection.
ALTA Technology Platform
Thermostability + Single-Shot Administration
ALTA uses highly scalable, commercially available equipment and ingredients that are already common in pharmaceuticals and generally recognized as safe (GRAS).
ALTA-enabled vaccines are engineered for extended shelf life allowing them to be easily transported anywhere in the world, stockpiled or distributed preventatively as part of emergency or military supplies. Creating a single-shot vaccine greatly increases adherence, with larger numbers of people being vaccinated and fully protected. The combination of reduced cold chain requirements during storage and transportation with single-shot administration enables vaccines to more easily reach underserved populations and geographies, helping to prevent disease and save lives.
Team


Colindres, MD, MBA Chief Executive Officer



Erickson Head of Research and Development Operations



Steadman Chief Technical Officer



Garcea, MD Co-Founder



Randolph, PhD Co-Founder
